Treatment of Psoriasis Vulgaris with Oral 1α,25‐Dihydroxyvitamin D<sub>3</sub>

Morimoto, Shigeto; Yoshikawa, Kunihiko; Kitano, Yukio; Imanaka, Shunji; Fukuo, Keisuke; Koh, Eitetsu; Hatori, Takashi; Zen, Ayman Al Haj; Nabata, T

doi:10.1111/j.1346-8138.1987.tb02997.x

Cited by 18 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason for the exclusion of oral vitamin D as a recommended treatment for psoriasis by both the NPF and AAD is unclear. Four different forms of oral vitamin D have been shown to be safe treatments for psoriasis dating back to the 1930s [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ], when oral vitamin D 2 was first found to be effective in treating a number of diseases in addition to psoriasis, including asthma [ 29 ], rheumatoid arthritis [ 30 , 31 ], rickets [ 32 ] and tuberculosis [ 33 , 34 , 35 , 36 , 37 , 38 , 39 ]. Sunshine, UVB phototherapy and cod liver oil, a concentrated food source of vitamin D, were also noted to be effective treatments for psoriasis [ 12 , 40 , 41 , 42 , 43 , 44 ], rickets [ 45 , 46 ] and TB [ 39 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 ] during that era.…”

Section: Introductionmentioning

confidence: 99%

Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications

McCullough

Lehrer

et al. 2021

Nutrients

View full text Add to dashboard Cite

Vitamin D, sunshine and UVB phototherapy were first reported in the early 1900s to control psoriasis, cure rickets and cure tuberculosis (TB). Vitamin D also controlled asthma and rheumatoid arthritis with intakes ranging from 60,000 to 600,000 International Units (IU)/day. In the 1980s, interest in treating psoriasis with vitamin D rekindled. Since 1985 four different oral forms of vitamin D (D2, D3, 1-hydroxyvitaminD3 (1(OH)D3) and 1,25-dihydroxyvitaminD3 (calcitriol)) and several topical formulations have been reported safe and effective treatments for psoriasis—as has UVB phototherapy and sunshine. In this review we show that many pre-treatment serum 25(OH)D concentrations fall within the current range of normal, while many post-treatment concentrations fall outside the upper limit of this normal (100 ng/mL). Yet, psoriasis patients showed significant clinical improvement without complications using these treatments. Current estimates of vitamin D sufficiency appear to underestimate serum 25(OH)D concentrations required for optimal health in psoriasis patients, while concentrations associated with adverse events appear to be much higher than current estimates of safe serum 25(OH)D concentrations. Based on these observations, the therapeutic index for vitamin D needs to be reexamined in the treatment of psoriasis and other diseases strongly linked to vitamin D deficiency, including COVID-19 infections, which may also improve safely with sufficient vitamin D intake or UVB exposure.

show abstract

Section: Introductionmentioning

confidence: 99%

Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications

McCullough

Lehrer

et al. 2021

Nutrients

View full text Add to dashboard Cite

show abstract

“…The central role of the VDR in regulation of different molecular pathways (including immune mechanisms) made 1,25(OH) 2 D 3 and its analogues therapeutically promising for a wide spectrum of clinical applications. Proof‐of‐concept of systemically applied vitamin D 3 in treating psoriasis patients has been demonstrated in clinical trials (20,21). Clinical use of 1,25(OH) 2 D 3 , however, in psoriasis and other (auto‐) immune diseases as a systemically applied immunomodulator is not suited because of its prominent calcium‐mobilizing effect that can lead to severe organ calcifications, bone resorption and organ failure (22–24).…”

Section: Introductionmentioning

confidence: 99%

Immunomodulation by a novel, dissociated Vitamin D₃ analogue

Zügel

Steinmeyer

May

et al. 2009

Experimental Dermatology

View full text Add to dashboard Cite

The biologically active metabolite of vitamin D3, 1alpha,25-dihydroxyvitamin D3, has potent immunomodulatory activity; however, its clinical use is limited because of its hypercalcaemic activity in anti-inflammatory active doses. Here, we present ZK203278, a novel, structurally different vitamin D3 analogue with profound immunomodulatory activities. It potently inhibits lymphocyte proliferation in the mixed lymphocyte reaction, and release of cytokines that are central in inflammation, such as TNFalpha and IL-12 in the low nanomolar range. Similarly, expression of cell-surface molecules involved in cell adhesion and antigen presentation, e.g. to T cells, is down-regulated on human monocytes by low nanomolar concentrations of ZK203278. Potent anti-inflammatory activity has been demonstrated also in vivo in rodent disease models. ZK203278 inhibited allergic contact dermatitis in rodents after oral administration in doses approximately two orders of magnitude below the hypercalcaemic threshold dose. Moreover, ZK203278 significantly prolonged skin allograft survival in rats in well-tolerated doses. Altogether ZK203278, in contrast to 1alpha,25-dihydroxyvitamin D3, exerts considerable immunomodulatory activity at non-hypercalcaemic dosages and may have therapeutic potential for immune disorders or transplant rejection.

show abstract

“…During the study, it was observed that a single dose at bedtime, rather than twice daily, helped to minimize the hypercalciuria. Of the 14 patients, ten showed a "significant clearing," whereas 4 patients had no benefit or only mild clinical response [135]. showed at least moderate improvement for 7 of 10 patients.…”

Section: Vitamin Dmentioning

confidence: 98%